*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.
OXLUMO® (lumasiran) is the first FDA-approved treatment for primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in infants, children and adults.1-3
How OXLUMO works in PH1
As an siRNA targeted specifically at the liver, OXLUMO harnesses RNAi, a natural process that reduces the production of a protein.1
RNA, ribonucleic acid; RNAi, RNA interference; siRNA, small interfering RNA.
OXLUMO is an RNA interference (RNAi) therapeutic targeted to the liver1
OXLUMO acts upstream of the metabolic defect in AGT to reduce oxalate production1
Mechanism of Action of OXLUMO
This video provides a brief overview of PH1 and how OXLUMO works.
There’s more to learn about OXLUMO
When you sign up, we will keep you informed with updates and resources.
Alnylam Assist™ provides support services for your patients throughout their treatment with OXLUMO.
Alnylam Assist™ includes patient services in key areas, including understanding insurance benefits and financial assistance options, helping ensure access to therapy, and providing PH1 disease education.
1. OXLUMO [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc. 2. Liebow A, Li X, Racie T, et al. J Am Soc Nephrol. 2017;28(2):494-503. 3. Hoppe B. Nat Rev Nephrol. 2012;8(8):467-475. 4. Milliner DS, Harris PC, Sas DJ, et al. GeneReviews®. University of Washington, Seattle; 1993-2022. 5. Cochat P, Rumsby G. N Engl J Med. 2013;369(7):649-658. 6. Cochat P, Hulton SA, Acquaviva C, et al. Nephrol Dial Transplant. 2012;27(5):1729-1736.